Trials
1 active
9 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).”In the company’s words, NCT05683457 on ClinicalTrials.gov
- Tested for
- Cytomegalovirus Infection
- Main trialPhase 2
- “The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.”In the company’s words, NCT05683457 on ClinicalTrials.gov
Other drugs for Cytomegalovirus Infection
- LB-DTK-MVLucasBio · Phase 1/2
- ArtesunateAmivas Inc. · Phase 2
Coming up1
- 6 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 6 Mar 2027 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | |
| Phase 3Terminated | 4 Nov 2025 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | |
| Phase 2Completed | 4 Jan 2023 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | |
| Phase 2Completed | 19 Jan 2026 | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | |
| Phase 2Withdrawn | 14 Feb 2027 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients | |
| Phase 1/2Completed | 12 May 2026 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | |
| Phase 1Completed | 28 Oct 2020 | Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults | |
| Phase 1Completed | 10 Aug 2023 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 | |
| Phase 1Completed | 27 Feb 2026 | A Study of Modified mRNA Vaccines in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026